JPS58113275A - Pressure-sensitive adhesive composition - Google Patents

Pressure-sensitive adhesive composition

Info

Publication number
JPS58113275A
JPS58113275A JP56210251A JP21025181A JPS58113275A JP S58113275 A JPS58113275 A JP S58113275A JP 56210251 A JP56210251 A JP 56210251A JP 21025181 A JP21025181 A JP 21025181A JP S58113275 A JPS58113275 A JP S58113275A
Authority
JP
Japan
Prior art keywords
cyclodextrin
sensitive adhesive
pressure
tape
adhesive composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP56210251A
Other languages
Japanese (ja)
Other versions
JPH0216289B2 (en
Inventor
Toshio Ito
俊男 伊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nichiban Co Ltd
Original Assignee
Nichiban Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nichiban Co Ltd filed Critical Nichiban Co Ltd
Priority to JP56210251A priority Critical patent/JPS58113275A/en
Publication of JPS58113275A publication Critical patent/JPS58113275A/en
Publication of JPH0216289B2 publication Critical patent/JPH0216289B2/ja
Granted legal-status Critical Current

Links

Abstract

PURPOSE:The titled composition that contains a clathrate compound from a substance with the steroid structure, thus showing high physiological activity of steroid with high stability. CONSTITUTION:A substance with the steroid structure such as fluorocinnolone acetonide is made into a clathrate compound using beta-cyclodextrin or gamma-cyclodextrin and the product is combined to produce the objective pressure-sensitive adhesive composition.

Description

【発明の詳細な説明】 本発明は治療に使用される粘着テープ用の感圧性接着剤
組成物(−関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to pressure sensitive adhesive compositions for adhesive tapes used in therapy.

従来ステロイド骨格を有する化合物、例えばヒドロコル
チゾン、ベタメタシンその他の副腎皮質ホルモン、テス
トステロン、エストロン、フロゲストロンその他の性ホ
ルモン、ジゴキシン、ジギトキシンその他の強心配糖体
、胆汁酸等は生理活性が強く、薬物として重要なものが
多く、古くから医薬品として利用されている。これらス
テロイド骨格を有する化合物の分子量はグθo−to。
Traditionally, compounds with a steroid skeleton, such as hydrocortisone, betamethacin and other adrenocortical hormones, testosterone, estrone, phlogestrone and other sex hormones, digoxin, digitoxin and other cardiac glycosides, and bile acids, have strong physiological activity and are important as drugs. Many of them have been used as medicines since ancient times. The molecular weight of these compounds having a steroid skeleton is θo-to.

内外で、ポリペプチド系ホルモンと比較して小さく、経
皮吸収性があるため軟こう、クリームなどの剤型で応用
されているものがある。
Domestically and internationally, some hormones are used in the form of ointments, creams, etc. because they are smaller than polypeptide hormones and can be absorbed through the skin.

本発明はステロイド骨格を有する化合物をシフロブキス
) IJンその他の包接化合物にして感圧性接着剤成分
中に含有させて、安定性がよく、薬理作用の高いステロ
イド化合物を含有する感圧性接着用のテープ剤を提供し
ようとするものである。
The present invention provides a pressure-sensitive adhesive containing a steroid compound with good stability and high pharmacological action, by converting a compound having a steroid skeleton into a clathrate compound such as schiflovkis, etc., and incorporating it into a pressure-sensitive adhesive component. The aim is to provide a tape agent.

シクロデキストリンは整数倍のグルコース単位が結1合
して環を形成しているものであって、α−シクロデキス
トリンはグルコース基6箇からなり、その環の空洞の大
きさは内径り、!又、深さ乙、7 Aであり、β−シク
ロデキストリンはグルコース基7箇からな番)、その環
の空洞の大きさは内径7.OA1深さ7.0Aであり、
γ−シクロデキストリンはグルコース基r箇からなり、
その空洞の大きさは内径♂、5k、深さ7.0λである
とされており、これらの空洞内に他の分子を取入れてい
わゆる包接化合物を形成するものであるが、空洞の大き
さの点でステロイド化合物の場合にはβ及びγ−シクロ
デキストリンが好適であり、β−シクロデキストリンの
場合は主としてステロイド:シクロデキストリン=/:
2、γ−シクロデキストリンの場合は主としてステロイ
ド:シクロデキストリン=2:3のそ、れぞれモル比で
包接化合物を形成するとされている。このステロイド・
シクロデキストリン包接化合物は溶解性、放出性、安定
性、バイオアベイラビリティ等がすぐれており、同一薬
効を得るのにステロイド化合物の単独使用に比しより少
量の使用で足りるばかりでなく、施用したさいの好まし
くない副作用等も最小限にとどめることができる。又従
来配合される感圧性接着剤成分の選択を必要としたフル
方ジノロンアセトニド、吉草酸ベタメタシンその他のス
テロイドも前述の如き包接化合物にして配合することに
より従来の如き感圧性接着剤成分の選択が不必要となる
ほか、放出性の点で感圧性接着剤成分中への配合に問題
のあった強心配糖体ジギトキシン等も包接化合物にする
ことによって所要の感圧性接着剤成分中への配合が可能
になった。例えば、前記フルオロンノロンアセトニドの
副腎皮質ホルモンの強さを示すMCKenzieの皮膚
蒼白化インデックスは/θ0であるが、これを感圧性接
着剤成分中(=配合してテープ剤とすると、前記蒼白化
インデックスがグ乙であるより弱い副腎皮質ホルモンで
あるフルドロキシコルチドを同含量に配合したテープ剤
よりも蒼白化作用が弱くなる。このため蒼白化インデッ
クスゲ乙であるフルドロコルチドをグμflea含有す
るテープ剤と同等の蒼白化作用を有するテープ剤を′得
るためには、フル方ジノロンアセトニドの含有量を約2
倍の!μ?/crA にしなければならない。これはテ
ープ剤からのフル方ジノロンアセトニドの放出性に難点
があるためであるが、このフルオシノ凸ンアセトニドを
前記β−シクロデキストリンの包接化合物にして配合す
るとフルドロキシコルチドとほぼ同じ含有量(グμt/
di )  にして同様の薬効が得られることが判った
Cyclodextrin is a ring in which an integral number of glucose units are bonded together to form a ring. α-cyclodextrin consists of 6 glucose groups, and the size of the cavity of the ring is the inner diameter. Also, the depth is 7 A, β-cyclodextrin has 7 glucose groups), and the size of the cavity of the ring is 7 A. OA1 depth is 7.0A,
γ-Cyclodextrin consists of r glucose groups,
The size of the cavity is said to be an inner diameter of ♂, 5k, and a depth of 7.0λ, and other molecules are incorporated into these cavities to form so-called clathrate compounds, but the size of the cavity In the case of steroid compounds, β- and γ-cyclodextrins are preferred, and in the case of β-cyclodextrin, mainly steroid:cyclodextrin=/:
2. In the case of γ-cyclodextrin, it is said that clathrate compounds are mainly formed at a molar ratio of steroid:cyclodextrin=2:3. This steroid
Cyclodextrin clathrate compounds have excellent solubility, release properties, stability, bioavailability, etc., and not only do they require smaller amounts to achieve the same medicinal efficacy than steroid compounds alone, but they can also be applied easily. Undesirable side effects can also be minimized. In addition, steroids such as fludinolone acetonide, betamethacin valerate, and others, which required selection of the pressure-sensitive adhesive components conventionally blended, can be blended as clathrate compounds as described above, so that they can be blended as conventional pressure-sensitive adhesive components. In addition, cardiac glycosides such as digitoxin, which had problems in being incorporated into pressure-sensitive adhesive components due to release properties, can be incorporated into pressure-sensitive adhesive components by making them into clathrate compounds. It is now possible to combine For example, the MCKenzie skin pallor index, which indicates the strength of the adrenocortical hormone, of the fluoronolone acetonide is /θ0, but if this is added to the pressure-sensitive adhesive component (= blended to make a tape), the pallor The pallor effect is weaker than a tape containing the same amount of fludroxycortide, which is a weaker adrenal corticosteroid with a weaker whitening index.For this reason, it contains fludrocortide, which has a lower pallor index, than μflea. In order to obtain a tape with a pallor effect equivalent to that of the tape, the content of fludinolone acetonide should be increased by approximately 2.
Double! μ? /crA. This is due to the difficulty in releasing fluocinolone acetonide from the tape, but if this fluocinoconvex acetonide is blended as a clathrate compound of the β-cyclodextrin, it contains almost the same amount as fludroxycortide. amount (μt/
It was found that similar medicinal effects could be obtained using di).

又心不全、心筋梗塞、不整脈などの疾患治療用の強心配
糖体1例えばジギタリス剤があり、このジギタリス剤で
はジギトキシンとジゴキシンが主として使用され、通常
は静脈注射あるいは経口投与により血液中の濃度を中毒
量の寸前いわゆる飽和量(約O0j〜/、5■)に抑え
ると共に所要濃度を持続させるため少量づつ例えば乙時
間毎にその縮量を服用等(二より補充する方法がとられ
ている従来このジギタリス剤の補充は該ジギタリス剤を
感圧性接着剤中に配合したテープ剤により経皮的イ;吸
収させることは困難であるとされていたが、これらジギ
タリス剤を前記同様シクロデキストリン等の包接化合物
にして配合したテープ剤の使用によって経皮的吸収が容
易にできることも判った実施例/ β−シクロデキヌトリン2.2♂f<2×10=モル)
を水、fOml中に入れ、約7θ℃に加熱して溶解し、
これにフル方ジノロンアセトニド0.22t3t(θ、
t X / 0−3モル)をアセトン!−に溶解して加
え、約5時間攪拌放冷した後、ν別された沈澱物を乾燥
してフル方ジノロンアセトニドのシクロデキストリン包
接化合物/、?、< fを得た。この包接化合物/、0
fをアセトン!θ−中に分散し、コーエチルへキシルア
クリレートざ夕重it%、酢酸ビニシ重量型量係、アク
リル酸!重量係からなるアクリル共重合体の酢酸エチル
・トルエン(9:/)溶液(固型分含址、23 %、3
0℃における溶液粘度2ポイズ)乙乙Oグに加えて約9
時間よく攪拌し、粘着液とした。この粘着液をシリコー
ン処理した剥離紙上に、溶剤揮散後の厚さり0μとなる
ように塗布し、室温で溶剤を揮散させ、釘に100℃で
7分間加熱して完全に溶剤を揮散させた後、厚さ700
μの片面マット加工、片面コロナ処理した軟質ポリエチ
レンフィルムのコロナ処理面に貼合せて、フル方ジノロ
ンアセトニド含有ポリエチレン粘着テープ片を得た。こ
のテープ片を2ydに切り取り、剥離紙を除去して、1
0−のメタノール中で30分間振とう、この抽出を3回
繰り返し、合計30m1の抽出液を得、これをシリカゲ
ルカラム(フロリジル)を通して粘着剤からの夾雑物を
除去後、乾燥して溶離液としてメタノール:水(、<:
g)を用いて高速液体クロマトグラフ(カラム二μmポ
ンダパックC−/♂)分析を行ったところ、フルオシノ
ロンアセトニド含有量はyμf/cdl に対し99.
♂チであった。
In addition, there are cardiac glycosides 1 for the treatment of diseases such as heart failure, myocardial infarction, and arrhythmia, such as digitalis drugs. Digitalis drugs mainly use digitoxin and digoxin, and are usually administered intravenously or orally to reduce the concentration in the blood to a toxic level. In order to suppress the amount to the so-called saturation amount (approx. Digitalis agents can be replenished transdermally using a tape containing the digitalis agent in a pressure-sensitive adhesive; it has been said that it is difficult to absorb these agents, but these digitalis agents can be replenished with cyclodextrin, etc., as described above. An example in which it was found that transdermal absorption could be easily achieved by using a tape formulation formulated as a compound / β-cyclodequinutrin 2.2♂f<2×10=mol)
into water, fOml, and heated to about 7θ℃ to dissolve,
To this, 0.22t3t(θ,
tX/0-3 mol) in acetone! After stirring and cooling for about 5 hours, the separated precipitate was dried to form a cyclodextrin clathrate compound of dinolone acetonide/? , < f was obtained. This clathrate /, 0
f for acetone! Dispersed in θ-, coethylhexyl acrylate, weight it%, vinyl acetate weight type, acrylic acid! Ethyl acetate/toluene (9:/) solution of acrylic copolymer consisting of weight ratio (contains solid content, 23%, 3%)
Solution viscosity at 0°C: 2 poise)
The mixture was thoroughly stirred for a long time to form a sticky liquid. This adhesive liquid was applied onto a silicone-treated release paper so that the thickness after solvent volatilization was 0μ, the solvent was volatilized at room temperature, and the nail was heated at 100°C for 7 minutes to completely volatilize the solvent. , thickness 700
A piece of polyethylene adhesive tape containing full-sided dinolone acetonide was obtained by laminating it on the corona-treated surface of a soft polyethylene film that had been subjected to matte treatment on one side and corona treatment on one side. Cut this tape piece into 2yd, remove the release paper, and
Shake for 30 minutes in 0-methanol and repeat this extraction three times to obtain a total of 30 ml of extract, which was passed through a silica gel column (Florisil) to remove impurities from the adhesive, dried, and used as an eluent. Methanol: Water (, <:
When high-performance liquid chromatography (column 2 μm Pondapak C-/♂) was analyzed using 2 μm column g), the fluocinolone acetonide content was 99.0 μf/cdl.
It was a male.

本テープ剤の薬効を比較するため、毛細血管収縮能を皮
膚蒼白化試験(二より検討した。比較のため、フルオシ
ノロンアセトニドをシクロデキストリンで包接しないで
同様に作成した粘着テープ片およびフルドロキシコルチ
ドを含有する市販の副腎皮質ホルモン含有テープ剤を加
えて試験を行った。試験は健常人2y名につき各人の背
部に直径/、!副の試料テープを貼り、テープ除去後2
時間、9時間及び?時間目の皮慮蒼白化の程度を検へ、
その結果を表/に示す。
In order to compare the medicinal efficacy of this tape preparation, the capillary constriction ability was examined in a skin pallor test (2). A test was conducted by adding a commercially available adrenocorticosteroid-containing tape containing fludroxycortide.The test was conducted on 2y healthy subjects.A sample tape with a diameter of /,! was applied to the back of each person, and after the tape was removed,
Time, 9 hours? Examine the degree of skin pallor after an hour.
The results are shown in Table/.

表     / 但しFA:フルオシノロンアセトニド FA−CD :フルオシノロンアセトニト°シクロデキ
ストリン包接化合物(薬剤 含量はフルオシノロンアセトニド 量で示す) FC−′ブルドロキジコルチド含有市販テープ判定基準
 +・・・明瞭な蒼白化 ±・・軽度の蒼白化 −・・反応なし 上記(7)表/の結果よりフルオシノロンアセトニド単
独の場合には、♂μグ肩の含量では比較対照としたフル
ドロキノコルチドグμ2肩とほぼ同等の薬効が窺えるが
、フルオシノロンアセトニドグμfAl では比較対照
より明らかに劣る蒼白化現象を示した。しかし、フルオ
シノロンアセトニド・シクロデキストリン包接化合物で
は、フルオシノロンアセトニド含量グμ2肩でも、フル
ドロキシコルチドグμt/cdの比較対照、あるいはフ
ルオシノロンアセトニド単独のときの♂μ?AI と比
較して同等あるいはそれ以上の蒼白化を示した。以上の
結果より、フルオシノロンアセトニドなど副腎皮質ホル
モンをテープ開化するにさいして、それらのシクロデキ
ストリン包接化合物を用いることはバイオアベイラビリ
ティを高める上で極めて有効であることが判明した。
Table / However, FA: fluocinolone acetonide FA-CD: fluocinolone acetonit ° cyclodextrin clathrate compound (drug content is indicated by the amount of fluocinolone acetonide) FC-' Commercially available tape containing brudroki dicortide determination Criteria +... Clear pallor ±... Mild pallor -... No reaction From the results in Table (7) above, in the case of fluocinolone acetonide alone, the content of the male μg shoulder was compared to the control. It appears that the medicinal efficacy is almost the same as that of Fludro Mushroom Curtidog μ2 Shoulder, but Fluocinolone Acetonidog μfAl showed a pallor phenomenon that was clearly inferior to that of the comparison control. However, in the case of fluocinolone acetonide/cyclodextrin clathrate compound, even if the fluocinolone acetonide content is equal to μ2, it is difficult to compare fluocinolone acetonide μt/cd or ♂μ when using fluocinolone acetonide alone. It showed the same or greater pallor compared to AI. From the above results, it has been found that the use of cyclodextrin inclusion compounds is extremely effective in increasing the bioavailability of adrenocortical hormones such as fluocinolone acetonide.

実施例コ 実施例/と同様の操作で吉草酸ベタメタシンo、、:z
3ztcθ、!×/θ−3モル)のβ−シクロデキスト
リン包接化合物7.3♂2を得た。この包接化合物/、
0グをアセトンj07!中に分散して、シリコーン粘着
剤(ダウコーニング社A3!;3;、固型分/!、!重
量%、使用溶剤トリフロロカーボン)922fに加えて
約9時間よく攪拌し、粘着液とした。この粘着液を片面
マット加工、片面コロナ処理した厚さ10θμの軟質ポ
リプロピレンフィルム上に溶剤揮散後の粘着剤の厚さ’
ioμになるように塗布し、室温で風乾後1.10O℃
に7分間加熱して溶剤を完全に除去し、ついでこの粘着
面をワックス処理したクレープ剥離紙で覆い吉草酸ベタ
メタシンをグμグΔイ含有する粘着テープ片を得た。
Betamethacin valerate o, :z was prepared in the same manner as in Example.
3ztcθ,! ×/θ−3 mol) β-cyclodextrin clathrate compound 7.3♂2 was obtained. This clathrate compound/
0g to acetone j07! The mixture was added to 922f of silicone adhesive (Dow Corning Co., Ltd. A3!;3;, solid content/!,!% by weight, solvent used: trifluorocarbon) and stirred well for about 9 hours to obtain a sticky liquid. The thickness of the adhesive after solvent volatilization was applied to a soft polypropylene film with a thickness of 10θμ, which had been treated with a matte finish on one side and a corona treatment on the other.
Apply to ioμ, air dry at room temperature, and then heat to 1.10°C.
The mixture was heated for 7 minutes to completely remove the solvent, and then the adhesive surface was covered with wax-treated crepe release paper to obtain an adhesive tape piece containing betamethacin valerate.

得られたテープ片の吉草酸ベタメタシン含有量はアセト
ンを抽出液として実施例/と同様に処理して、水ニアセ
トニトリルCso:to>r:てμmボンダパックC−
/♂を用いて高速液体クロマトグラフにより定量したと
ころグμf/cr/l l二対してタデ、3チの含量を
示した。このテープ片の血管収縮試験結果は表2に示す
とおり、シクロデキストリン包接化合物を使用しない含
1&μf/crlのものよりも良好であり、含量グμf
/cr/lでシクロデキストリン包接化合物を使用しな
い含量にμF/、−dのもの、あるいはフルドロキシコ
ルチドダμf/cd 含有の比較対照と同等あるいはそ
れ以上の成績を示した。従って吉草酸ベタメタシンにお
いても、シクロデキストリン包接化合物の応用はパイオ
アペリラビリティを向上させる上で有効あり、より少な
い薬剤の使用でより高い効果を上げ得ることが明らかで
ある。この技術の応用によって副腎皮質ホルモンだけで
なく1強心配糖体などステロイド骨格を有する有用な薬
剤のテープ化が可能である。
The content of betamethacin valerate in the obtained tape piece was determined by treating it in the same manner as in Example/using acetone as an extractant, using water, niacetonitrile, Cso:to>r:μm Bondapak C-
Quantification by high-performance liquid chromatography using /♂ showed that the content was 3 μf/cr/l versus 3 μf/♂. As shown in Table 2, the results of the vasoconstriction test for this tape piece were better than those containing 1&μf/crl that did not use a cyclodextrin clathrate;
/cr/l showed the same or better performance than the comparison control containing μF/, -d without cyclodextrin clathrate, or fludroxycortide μf/cd. Therefore, it is clear that the application of cyclodextrin clathrate compounds to betamethacin valerate is effective in improving the bioappellability, and that a higher effect can be achieved with the use of a smaller amount of drug. By applying this technology, it is possible to tape not only adrenocortical hormones but also useful drugs with steroid skeletons such as cardiac glycosides.

下記の表2は健常人2f名につき、各人の背部に直径/
、!副の試料テープを貼り、実施例/の場合と同様にし
て皮膚蒼白化の程度を検べた結果である。
Table 2 below shows the diameter/diameter on each person's back for 2f healthy people.
,! The results were obtained by applying a secondary sample tape and examining the degree of skin pallor in the same manner as in Example.

(以下余白) 表、  2 テープ除去後の時間   7時間    2時間   
 グ時間但しBMV  ・・・吉草酸ペタメタシンBM
V−CD・・・吉草酸ベタメタシン・シクロデキストリ
ン包接化合物(薬剤台 量は吉草酸ベタメタシンとして) FC・・・フルドロキシコルチド含有市販テープ判定基
準 +・・・明瞭な蒼白化 ±・・・軽度の蒼白化 −・・反応なし
(Left below) Table 2 Time after tape removal 7 hours 2 hours
However, BMV...Petamethacin valerate BM
V-CD... Betamethacin valerate/cyclodextrin clathrate (drug dosage is as betamethacin valerate) FC... Judgment criteria for commercially available tapes containing fludroxycortide +... Clear pallor ±... Mild pallor - no reaction

Claims (1)

【特許請求の範囲】 / ステロイド骨格を有する物質を包接化合物にして配
合した感圧性接着剤組成物。 コ 包接化合物がシクロデキストリンの包接化合物であ
る特許請求の範囲第1項記載の感圧性接着剤組成物。 3 シクロデキストリンがβ−シクロデキストリンであ
る特許請求の範囲第2項記載の感圧性接着用組成物。 グ シクロデキストリンがγ−シクロデキストリンであ
る特許請求の範囲第2項記載の感圧性接着剤組成物。
[Claims] / A pressure-sensitive adhesive composition containing a substance having a steroid skeleton as an clathrate compound. The pressure-sensitive adhesive composition according to claim 1, wherein the clathrate is a cyclodextrin clathrate. 3. The pressure-sensitive adhesive composition according to claim 2, wherein the cyclodextrin is β-cyclodextrin. 3. The pressure-sensitive adhesive composition according to claim 2, wherein the cyclodextrin is γ-cyclodextrin.
JP56210251A 1981-12-28 1981-12-28 Pressure-sensitive adhesive composition Granted JPS58113275A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56210251A JPS58113275A (en) 1981-12-28 1981-12-28 Pressure-sensitive adhesive composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56210251A JPS58113275A (en) 1981-12-28 1981-12-28 Pressure-sensitive adhesive composition

Publications (2)

Publication Number Publication Date
JPS58113275A true JPS58113275A (en) 1983-07-06
JPH0216289B2 JPH0216289B2 (en) 1990-04-16

Family

ID=16586276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56210251A Granted JPS58113275A (en) 1981-12-28 1981-12-28 Pressure-sensitive adhesive composition

Country Status (1)

Country Link
JP (1) JPS58113275A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63230635A (en) * 1987-03-09 1988-09-27 アルザ・コーポレーション Prevention of contact allergy by simultaneous administration of corticosteroid and sensitizing drug
US5089482A (en) * 1988-07-01 1992-02-18 Hermens Walter A J J Pharmaceutical compositions for nasal administration containing steroid hormones and dimethyl-β-cyclodextrin
EP0613486A1 (en) * 1991-09-23 1994-09-07 Cerestar USA, Inc. Improved adhesives and sealants
WO2001013968A1 (en) * 1999-08-25 2001-03-01 Avery Dennison Corporation Cyclodextrin containing pressure sensitive adhesives
JP2006508940A (en) * 2002-10-31 2006-03-16 トランスファーマ メディカル リミテッド Transdermal delivery system for water insoluble drugs

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63230635A (en) * 1987-03-09 1988-09-27 アルザ・コーポレーション Prevention of contact allergy by simultaneous administration of corticosteroid and sensitizing drug
US5089482A (en) * 1988-07-01 1992-02-18 Hermens Walter A J J Pharmaceutical compositions for nasal administration containing steroid hormones and dimethyl-β-cyclodextrin
EP0613486A1 (en) * 1991-09-23 1994-09-07 Cerestar USA, Inc. Improved adhesives and sealants
EP0613486A4 (en) * 1991-09-23 1995-04-05 American Maize Prod Co Improved adhesives and sealants.
WO2001013968A1 (en) * 1999-08-25 2001-03-01 Avery Dennison Corporation Cyclodextrin containing pressure sensitive adhesives
JP2003507536A (en) * 1999-08-25 2003-02-25 アベリー・デニソン・コーポレイション Pressure-sensitive adhesive containing cyclodextrin
JP2006508940A (en) * 2002-10-31 2006-03-16 トランスファーマ メディカル リミテッド Transdermal delivery system for water insoluble drugs
JP4831968B2 (en) * 2002-10-31 2011-12-07 トランスファーマ メディカル リミテッド Transdermal delivery system for water insoluble drugs

Also Published As

Publication number Publication date
JPH0216289B2 (en) 1990-04-16

Similar Documents

Publication Publication Date Title
EP0744944B1 (en) Sexual steroid-containing transdermal therapeutic systems
EP0186019B1 (en) Medicated dressing
EP0062682B1 (en) Adhesive preparation for heart disease and process for its preparation
WO1988001170A1 (en) Steroidal drug-containing preparation for external use
CH651213A5 (en) ADHESIVE PLASTER WITH ANTIPHLOGISTIC AND ANALGETIC EFFECT.
TW590776B (en) Antipsoriatic nail polish
JP2012092130A (en) Transdermal hormone delivery system: composition and method
US5236906A (en) Topical therapeutic preparation
CN104983669B (en) tablet containing steroid hormone
EP1103260A2 (en) Transdermal system for the administration of clonidine
JPS58113275A (en) Pressure-sensitive adhesive composition
JP2646025B2 (en) Lotion containing corticosteroid
JPS6310716A (en) Beta-stimulation agent for external use
CN108451934A (en) A kind of transdermal patch and preparation method thereof containing rotigotine
DE112015003260T5 (en) Production method for an antithyroid ointment for external use
DE19546024C2 (en) Transdermal pharmaceutical preparation and its production
JPH0333688B2 (en)
JPS62153227A (en) Percutaneous, permucous preparation
JP3575033B2 (en) External preparation
JPH09169635A (en) Percutaneous absorption preparation
Bodor et al. Enhanced activity of topical hydrocortisone by competitive binding of corticosteroid-binding globulin
DE19830651A1 (en) Plaster containing steroids, process for its production and use
JPS6379820A (en) Pharmaceutical formulation for percutaneous administration
Patil et al. Development and evaluation of transdermal gel of acyclovir using Nerolidol as penetration enhancer
JP2882843B2 (en) Agent for improving portal hypertension